Europe Iliac Stent Market Size, Share & Trends Analysis Report By Artery Lesions (Common Iliac Artery Lesions, Severe Calcified Lesions, and Complete Obstructive Lesions), By End-use, By Country and Growth Forecast, 2023 - 2030

Europe Iliac Stent Market Size, Share & Trends Analysis Report By Artery Lesions (Common Iliac Artery Lesions, Severe Calcified Lesions, and Complete Obstructive Lesions), By End-use, By Country and Growth Forecast, 2023 - 2030


The Europe Iliac Stent Market would witness market growth of 5.5% CAGR during the forecast period (2023-2030).

The Germany market dominated the Europe Iliac Stent Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $87.7 million by 2030. The UK market is exhibiting a CAGR of 4.5% during (2023 - 2030). Additionally, The France market would experience a CAGR of 6.4% during (2023 - 2030).

Regulatory approvals, labelling indications, and post-market surveillance requirements imposed by regulatory agencies influence the adoption of iliac stent procedures and market access for stent manufacturers. Conformity to regulatory standards, adherence to good manufacturing practices (GMP), and compliance with safety and efficacy requirements are essential for obtaining marketing authorization and ensuring product quality and patient safety.

Regulatory bodies are vital in assessing the efficacy and safety of these using premarket review procedures, post-market surveillance initiatives, and continuous monitoring of unfavourable occurrences, hence influencing market dynamics and adoption patterns. Moreover, economic factors, including reimbursement policies, healthcare financing mechanisms, and cost-effectiveness considerations, impact the adoption of procedures and reimbursement decisions by payers and healthcare providers.

The UK has a considerable burden of PAD, with a significant proportion of the population affected by arterial occlusive disease. PAD often leads to symptomatic iliac artery stenosis or occlusions, necessitating vascular interventions such as its placement. According to the National Library of Medicine, about 15% to 20% of the UK population aged 55 to 75 years have evidence of lower extremity PAD on objective testing. Hence, the region’s high healthcare expenditure and prevalence of PAD drive the market’s growth.

Based on Artery Lesions, the market is segmented into Common Iliac Artery Lesions, Severe Calcified Lesions, and Complete Obstructive Lesions. Based on End-use, the market is segmented into Hospitals, Outpatient Facilities, and Others. Based on Type, the market is segmented into Self-expandable Stents, Balloon-expandable Stents, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

List of Key Companies Profiled
  • Becton, Dickinson and Company
  • Abbott Laboratories
  • Boston Scientific Corporation
  • W. L. Gore & Associates, Inc.
  • Medtronic PLC
  • Cook Medical, Inc.(Cook Group)
  • Terumo Corporation
  • iVascular S.L.U.
  • Getinge AB
  • Biotronik SE & Co. KG
Europe Iliac Stent Market Report Segmentation

By Artery Lesions
  • Common Iliac Artery Lesions
  • Severe Calcified Lesions
  • Complete Obstructive Lesions
By End-use
  • Hospitals
  • Outpatient Facilities
  • Others
By Type
  • Self-expandable Stents
  • Balloon-expandable Stents
  • Others
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Iliac Stent Market, by Artery Lesions
1.4.2 Europe Iliac Stent Market, by End-use
1.4.3 Europe Iliac Stent Market, by Type
1.4.4 Europe Iliac Stent Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Opportunities
3.2.3 Market Restraints
3.2.4 Market Challenges
3.3 Porter’s Five Forces Analysis
Chapter 4. Europe Iliac Stent Market by Artery Lesions
4.1 Europe Common Iliac Artery Lesions Market by Country
4.2 Europe Severe Calcified Lesions Market by Country
4.3 Europe Complete Obstructive Lesions Market by Country
Chapter 5. Europe Iliac Stent Market by End-use
5.1 Europe Hospitals Market by Country
5.2 Europe Outpatient Facilities Market by Country
5.3 Europe Others Market by Country
Chapter 6. Europe Iliac Stent Market by Type
6.1 Europe Self-expandable Stents Market by Country
6.2 Europe Balloon-expandable Stents Market by Country
6.3 Europe Others Market by Country
Chapter 7. Europe Iliac Stent Market by Country
7.1 Germany Iliac Stent Market
7.1.1 Germany Iliac Stent Market by Artery Lesions
7.1.2 Germany Iliac Stent Market by End-use
7.1.3 Germany Iliac Stent Market by Type
7.2 UK Iliac Stent Market
7.2.1 UK Iliac Stent Market by Artery Lesions
7.2.2 UK Iliac Stent Market by End-use
7.2.3 UK Iliac Stent Market by Type
7.3 France Iliac Stent Market
7.3.1 France Iliac Stent Market by Artery Lesions
7.3.2 France Iliac Stent Market by End-use
7.3.3 France Iliac Stent Market by Type
7.4 Russia Iliac Stent Market
7.4.1 Russia Iliac Stent Market by Artery Lesions
7.4.2 Russia Iliac Stent Market by End-use
7.4.3 Russia Iliac Stent Market by Type
7.5 Spain Iliac Stent Market
7.5.1 Spain Iliac Stent Market by Artery Lesions
7.5.2 Spain Iliac Stent Market by End-use
7.5.3 Spain Iliac Stent Market by Type
7.6 Italy Iliac Stent Market
7.6.1 Italy Iliac Stent Market by Artery Lesions
7.6.2 Italy Iliac Stent Market by End-use
7.6.3 Italy Iliac Stent Market by Type
7.7 Rest of Europe Iliac Stent Market
7.7.1 Rest of Europe Iliac Stent Market by Artery Lesions
7.7.2 Rest of Europe Iliac Stent Market by End-use
7.7.3 Rest of Europe Iliac Stent Market by Type
Chapter 8. Company Profiles
8.1 Becton, Dickinson, and Company
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Trials and Approvals:
8.1.6 SWOT Analysis
8.2 Abbott Laboratories
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 SWOT Analysis
8.3 Boston Scientific Corporation
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Trials and Approvals:
8.3.6 SWOT Analysis
8.4 W. L. Gore & Associates, Inc.
8.4.1 Company Overview
8.4.2 SWOT Analysis
8.5 Medtronic PLC
8.5.1 Company overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Trials and Approvals:
8.5.6 SWOT Analysis
8.6 Cook Medical, Inc. (Cook Group)
8.6.1 Company Overview
8.6.2 SWOT Analysis
8.7 Terumo Corporation
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Trials and Approvals:
8.7.5.2 Product Launches and Product Expansions:
8.7.6 SWOT Analysis
8.8 iVascular S.L.U.
8.8.1 Company Overview
8.8.2 SWOT Analysis
8.9 Getinge AB
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Trials and Approvals:
8.9.6 SWOT Analysis
8.10. Biotronik SE & Co. KG
8.10.1 Company Overview
8.10.2 SWOT Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings